SCHEMBL4287555

SCHEMBL4287555

CN(C(=O)CNC(=O)OC(C)(C)C)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 13/20 0.59
CDC7 O00311 11/20 0.59
PRKACA P17612 9/20 0.59
CDK2 P24941 9/20 0.59
ROCK1 Q13464 9/20 0.59
GSK3B P49841 8/20 0.59
CDK1 P06493 7/20 0.59
GSK3A P49840 7/20 0.59
CDK5 Q00535 7/20 0.59
PRKCD Q05655 7/20 0.59
DYRK1A Q13627 7/20 0.59
CDC42BPA Q5VT25 7/20 0.59
AURKB Q96GD4 7/20 0.59
AURKA O14965 6/20 0.59
AKT1 P31749 6/20 0.59
CLK4 Q9HAZ1 6/20 0.59
MKNK2 Q9HBH9 6/20 0.59
RPS6KA3 P51812 6/20 0.59
SGK2 Q9HBY8 6/20 0.59
PRKCG P05129 6/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3667170 0.89 ROCK2 (0.66) ROCK2CDC7PRKACACDK2ROCK1
SCHEMBL4287558 0.84 ROCK2 (0.55) ROCK2CDC7PRKACACDK2ROCK1
SCHEMBL3665661 0.75 GSK3B (1.00) ROCK2CDC7PRKACACDK2ROCK1
SCHEMBL4287563 0.74 CDC7 (0.55) ROCK2CDC7PRKACACDK2ROCK1
SCHEMBL3666406 0.74 ROCK2 (0.71) ROCK2CDC7PRKACACDK2ROCK1
SCHEMBL3667213 0.73 GSK3B (0.79) ROCK2CDC7PRKACACDK2ROCK1
SCHEMBL3670360 0.73 GSK3B (0.84) ROCK2CDC7PRKACACDK2ROCK1
SCHEMBL3671481 0.72 ROCK2 (0.71) ROCK2CDC7PRKACACDK2ROCK1
SCHEMBL3667233 0.72 ROCK2 (0.66) ROCK2CDC7PRKACACDK2ROCK1
SCHEMBL3668848 0.72 GSK3B (1.00) ROCK2CDC7PRKACACDK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 ROCK2 48/4885CDC7 8/4885PRKACA 178/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 ROCK2 48/4885CDC7 8/4885PRKACA 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.